The effect of levodopa dose and body weight on dyskinesia in a prevalent population of people with Parkinson's disease

Parkinsonism Relat Disord. 2011 Jan;17(1):27-9. doi: 10.1016/j.parkreldis.2010.10.005. Epub 2010 Nov 3.

Abstract

Aims and objectives: We aimed to investigate the effect of active dose and dose per kilogram (kg) of body weight of levodopa on the occurrence of dyskinesia within a prevalent population of people with PD.

Methods: Of 106 prevalent cases, 75 (70.8%; 38 males, 37 females) agreed to assessment by a member of the research team. Demographic information, weight and height were recorded. Patients were assessed using a range of rating scales including the Unified Parkinson's Disease Rating Scale. Patients were asked specifically: 'Do you have, or have you ever had, dyskinesia?'.

Results: Nine patients (12.0%) reported dyskinesia. Patient reported dyskinesia was significantly associated with greater years since diagnosis (r=0.309, p=0.007), higher levodopa equivalent dose (r=0.406, p<0.001) and levodopa equivalent dose per kg body weight (r=0.375, p<0.001). Using logistic regression, active levodopa dose, unadjusted for body weight, was an independent predictor of dyskinesia.

Conclusions: Adjusting levodopa dose for body weight did not increase its degree of correlation with patient reported dyskinesia.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antiparkinson Agents / administration & dosage*
  • Antiparkinson Agents / therapeutic use*
  • Body Weight / physiology*
  • Dose-Response Relationship, Drug
  • Dyskinesias / drug therapy*
  • Dyskinesias / etiology
  • Female
  • Humans
  • Levodopa / administration & dosage*
  • Levodopa / therapeutic use*
  • Logistic Models
  • Male
  • Middle Aged
  • Parkinson Disease / complications
  • Parkinson Disease / drug therapy*
  • Prognosis

Substances

  • Antiparkinson Agents
  • Levodopa